Novo Nordisk 以司美格鲁肽酒精研究与LX9851试验扩展管线

Novo Nordisk (NYSE:NVO) is exploring semaglutide as a potential treatment for alcohol use disorder, expanding beyond its current uses in diabetes and obesity. The company has also begun Phase 1 trials for LX9851, an oral obesity and metabolic disorder drug developed with Lexicon Pharmaceuticals. These moves highlight ongoing clinical work in metabolic and related conditions, with implications for future treatment options. Novo Nordisk is currently trading at $43.88, with the share price up 6.

该内容为新闻快讯，正文已简化。